What is Chardan Capital’s Estimate for iBio FY2025 Earnings?

iBio, Inc. (NYSE:IBIO) – Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for iBio in a note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae expects that the company will earn ($1.53) per share for the year. The consensus estimate for iBio’s current full-year earnings is ($1.74) per share.

Separately, StockNews.com raised shares of iBio to a “sell” rating in a research note on Tuesday, March 18th.

iBio Stock Performance

NYSE:IBIO opened at $4.31 on Thursday. iBio has a 52-week low of $1.50 and a 52-week high of $6.89. The stock has a fifty day simple moving average of $4.07 and a 200-day simple moving average of $3.02. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.05.

Institutional Trading of iBio

An institutional investor recently raised its position in iBio stock. Geode Capital Management LLC lifted its holdings in shares of iBio, Inc. (NYSE:IBIO) by 52.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,797 shares of the company’s stock after acquiring an additional 28,775 shares during the quarter. Geode Capital Management LLC owned about 0.85% of iBio worth $205,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.90% of the company’s stock.

Insiders Place Their Bets

In related news, Director David Arkowitz acquired 18,382 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were acquired at an average cost of $2.72 per share, for a total transaction of $49,999.04. Following the acquisition, the director now directly owns 18,382 shares in the company, valued at approximately $49,999.04. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.58% of the company’s stock.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.